SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

8-K
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 8-K on 08/09/2018
Entire Document
 

 

 

Item 2.02Results of Operations and Financial Condition

 

On August 9, 2018, Protalix BioTherapeutics, Inc. issued a press release announcing its financial results for the period ended June 30, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits

 

(d)Exhibits

 

99.1Press release dated August 9, 2018.